Effect of Gefitinib on Brain Metastases From Non-Small Cell Lung Cancer—Two Case Reports—
N Nishi, S Kawai, T Yonezawa, K Fujimoto… - Neurologia medico …, 2006 - jstage.jst.go.jp
Two patients with non-small cell lung cancer presented with multiple brain metastases. They
received gefitinib orally for the treatment of the primary lung lesions. About one month later,
the brain metastases unexpectedly disappeared or became smaller. The patients survived
without recurrence of brain metastases and growth of lung lesions for 3–4 years. Gefitinib is
a selective epidermal growth factor receptor tyrosine kinase inhibitor and is approved for use
in the treatment of non-small cell lung cancer. Gefitinib may be very effective for multiple …
received gefitinib orally for the treatment of the primary lung lesions. About one month later,
the brain metastases unexpectedly disappeared or became smaller. The patients survived
without recurrence of brain metastases and growth of lung lesions for 3–4 years. Gefitinib is
a selective epidermal growth factor receptor tyrosine kinase inhibitor and is approved for use
in the treatment of non-small cell lung cancer. Gefitinib may be very effective for multiple …
Effect of Gefitinib on Brain Metastases From Non-Small Cell Lung Cancer-Two Case Reports
N Noriyuki, K Shozo, Y Taiji, F Kenta… - Neurologia medico …, 2006 - cir.nii.ac.jp
抄録 Two patients with non-small cell lung cancer presented with multiple brain metastases.
They received gefitinib orally for the treatment of the primary lung lesions. About one month
later, the brain metastases unexpectedly disappeared or became smaller. The patients
survived without recurrence of brain metastases and growth of lung lesions for 3-4 years.
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor and is
approved for use in the treatment of non-small cell lung cancer. Gefitinib may be very …
They received gefitinib orally for the treatment of the primary lung lesions. About one month
later, the brain metastases unexpectedly disappeared or became smaller. The patients
survived without recurrence of brain metastases and growth of lung lesions for 3-4 years.
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor and is
approved for use in the treatment of non-small cell lung cancer. Gefitinib may be very …
以上显示的是最相近的搜索结果。 查看全部搜索结果